Account
Browse

Pierce Corporate Finance Provides Valuation Report for Innovative Diabetes and Obesity Management Enterprise.

Pierce Corporate Finance Provides Valuation Report for Innovative Diabetes and Obesity Management Enterprise.

Pierce Corporate Finance Provides Valuation Report for Innovative Diabetes and Obesity Management Enterprise.

Posted: 04/12/2023

Pierce Corporate Finance Limited has recently been appointed by Oviva AG to provide advisory services ahead of the issue of Ordinary Share Options to key employees, members of the Board and Consultants.

Oviva has, to date, received over €100 Million in investment to develop innovative digital treatments for diabetes and obesity. The Company collaborates with specialist dieticians, nutritionists, doctors, health coaches, psychologists, wellbeing practitioners and exercise therapists with a mission to build a healthier future for patients.

Founded in Switzerland in 2014, Oviva developed an interactive app to provide support and advice and over the course of the following 2 years commenced working with approximately 100 doctors and clinics across Europe. By 2022, the business has reached over 500k patients, increased its employee base to 600 and widened its range of behaviour change therapies. Oviva is partnered in the UK with the NHS and NHS Scotland, active in Germany, France and Switzerland and growing rapidly.

Oviva AG Chairman, Simon Cartmell, said “Oviva is an international company at the forefront of the treatment of diabetes and obesity through the implementation of world-leading technology. With operations throughout the UK and Europe, the attraction and retention of key staff members is integral to the continued success of the business. The support provided by Pierce Corporate Finance was key in allowing us to design a share scheme to motivate and retain staff who are fundamental to achieving the next stage of our development.”

Pierce Director Steve Bell said “Health systems around the world face an increasing challenge from the issues surrounding diabetes and obesity. It was a pleasure to have advised Simon and the Board of Oviva on this next stage of development.”